ReviewCommunications medicine2025
Multi-omic insights of preeclampsia and cardiovascular health outcomes.
Review in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Second-trimester multimetabolite panel for early preeclampsia rule-out.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Pregnancy as a Window for Hypertension and Cardiovascular Prevention in Women: A Life-Course Perspective Based on the 2025 ESC Guidelines.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Multi-Omics for Mothers and Infants (MOMI) Consortium: a global initiative to study adverse pregnancy outcomes.Journal of global health · 2026Article
- Epigenetic mechanisms in preeclampsia: translational therapeutic strategies and precision-medicine perspectives.Journal of medicine and life · 2026Review
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a complex, hypertensive pregnancy disorder which is linked to an increased cardiovascular disease risk in both mothers and their offspring. Maternal haemodynamic adaptation during gestation is essential for adequate foetal nutrient supply and development, fundamentally shaping the offspring's cardiovascular health trajectory. In preeclampsia, this process is disrupted, leading to lasting effects for both the mother and the child. While the clinical features of preeclampsia in this context have been subject to extensive investigation, it remains a critical challenge to elucidate the molecular mechanisms underpinning its long-term cardiovascular consequences. This review synthesises multi-omics, including genomics, epigenomics, transcriptomics and metabolomics, and systems-biology insights to elucidate mechanisms, identify candidate biomarkers, and shape personalised medicine approaches. By bridging molecular and clinical understanding, we discuss how these approaches uncover prenatal adversity from preeclampsia exposure influencing cardiovascular disease risk in mothers and offspring, offering a roadmap to improve long-term cardiovascular outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.